These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 16106586)

  • 1. Rasagiline.
    Schapira A; Bate G; Kirkpatrick P
    Nat Rev Drug Discov; 2005 Aug; 4(8):625-6. PubMed ID: 16106586
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease.
    Chen JJ; Swope DM
    J Clin Pharmacol; 2005 Aug; 45(8):878-94. PubMed ID: 16027398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rasagiline as a therapy for Parkinson's disease (PD).
    Hermanowicz N
    Am J Geriatr Pharmacother; 2007 Jun; 5(2):174-5; author reply 175-6. PubMed ID: 17719520
    [No Abstract]   [Full Text] [Related]  

  • 5. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAO inhibitors.
    Keller D
    Cleve Clin J Med; 2011 Feb; 78(2):81; author reply 81. PubMed ID: 21365960
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.
    Marconi S; Zwingers T
    Eur Rev Med Pharmacol Sci; 2014 Jul; 18(13):1879-82. PubMed ID: 25010617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reexamination of the TEMPO Study.
    Shults CW
    Arch Neurol; 2005 Aug; 62(8):1320; author reply 1321. PubMed ID: 16087778
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.
    Jost WH; Friede M; Schnitker J
    Eur Rev Med Pharmacol Sci; 2014 Nov; 18(22):3349. PubMed ID: 25491607
    [No Abstract]   [Full Text] [Related]  

  • 10. [Rasagiline is not for all Parkinson disease patients: the ADAGIO study].
    van Laar T; Boon AJ; Bloem BR
    Ned Tijdschr Geneeskd; 2010; 154():A2496. PubMed ID: 20977789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rasagiline in motor fluctuations].
    Miletzki A
    Fortschr Neurol Psychiatr; 2005 Sep; 73(9):488. PubMed ID: 16217881
    [No Abstract]   [Full Text] [Related]  

  • 12. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
    Fernandez HH; Chen JJ
    Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline.
    Degli Esposti L; Piccinni C; Sangiorgi D; Nobili F; Buda S
    Neurol Sci; 2016 Feb; 37(2):227-34. PubMed ID: 26474874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2005 Jul; 28(7):224-7. PubMed ID: 16038119
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of Selegiline and Rasagiline Therapies in Parkinson Disease: A Real-life Study.
    Peretz C; Segev H; Rozani V; Gurevich T; El-Ad B; Tsamir J; Giladi N
    Clin Neuropharmacol; 2016; 39(5):227-31. PubMed ID: 27438181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rasagiline. Parkinson's disease: a simple me-too.
    Prescrire Int; 2006 Dec; 15(86):220. PubMed ID: 17167927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rasagiline. Teva Pharmaceutical.
    Kupsch A
    Curr Opin Investig Drugs; 2002 May; 3(5):794-7. PubMed ID: 12090555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Prog Neurobiol; 2010 Nov; 92(3):330-44. PubMed ID: 20600573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rasagiline: effectiveness and protection in Parkinson's disease].
    Pagonabarraga J; Kulisevsky J
    Rev Neurol; 2010 Nov; 51(9):535-41. PubMed ID: 20979033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.